Based on the results, adalimumab is deemed an effective treatment for AS, showcasing its potential as a first-line therapeutic option. Notably, no significant increase in adverse events was observed compared to placebo. However, the conclusion emphasizes the need for further studies with extended follow-up durations to ascertain the long-term efficacy and safety of adalimumab in AS management. This systematic review provides valuable insights supporting the use of adalimumab in the treatment of AS and underscores the importance of ongoing investigations into its long-term effects to optimize its clinical utilization in AS patients.
Keyphrases
- rheumatoid arthritis
- ankylosing spondylitis
- systematic review
- juvenile idiopathic arthritis
- end stage renal disease
- disease activity
- chronic kidney disease
- hidradenitis suppurativa
- ulcerative colitis
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- clinical trial
- randomized controlled trial
- meta analyses
- prognostic factors
- combination therapy
- systemic lupus erythematosus
- replacement therapy